Residents say this information made them feel prepared and motivated
Eating Disorders Alliance Welcomes Ban on Compounded GLP-1 Receptor Agonists MEDIA RELEASE March 23, 2024 The Eating Disorders Alliance (EDA), a coalition of leading eating disorder organisations in Australia and New Zealand, is encouraged to see the impact of our national advocacy campaign to address the significant medical risks posed by inappropriately promoted or prescribed weight loss products, particularly compounded GLP-1 receptor agonist analogues (GLP-1RAs)
In rodent animal models, GLP-1RAs increased thyroid paracellular cell (C-cell) proliferation and the incidence of tumors
We monitored the survival of both WT and LivPGC-1 mice for 24 hours after the i.p
Heres what you need to know about this stunningly effective new resource we now have to supplement diet and exercise for weight loss
These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease." While this and other trials continue to show the cardio-protective effects of tirzepatide, cost has been a major barrier for many patients
